XGNHealthcare · Diagnostics & ResearchThe 7 Wall Street analysts covering Exagen, Inc. hold a median 12-month price target of $8 — +70.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 1 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Exagen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (74): Smaller than most of the companies we track.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Exagen, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on XGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +70.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 June 2026 | Roth Capital | Initiates | Buy | $8.00 |
| 12 May 2026 | BTIG | Maintains | Buy | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 11 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 11 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 11 Mar 2026 | Keybanc | Maintains | Overweight | — |
| 10 Mar 2026 | BTIG | Maintains | Buy | — |
| 24 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 17 Feb 2026 | BTIG | Maintains | Buy | — |
| 30 Jan 2026 | B. Riley Securities | Reiterates | Buy | — |
| 10 Nov 2025 | BTIG | Maintains | Buy | — |
| 5 Nov 2025 | B. Riley Securities | Reiterates | Buy | — |
| 27 Oct 2025 | Canaccord Genuity | Maintains | Buy | — |
| 22 Oct 2025 | BTIG | Maintains | Buy | — |
| 14 Oct 2025 | Keybanc | Maintains | Overweight | — |
| 11 Sept 2025 | B. Riley Securities | Initiates | Buy | — |
| 30 July 2025 | Canaccord Genuity | Maintains | Buy | — |
| 30 July 2025 | Keybanc | Upgrade | Overweight | — |
| 23 July 2025 | Craig-Hallum | Initiates | Buy | — |
| 15 May 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 58% of US stocks
Cheaper than 13% of US stocks
Cheaper than 84% of US stocks
Higher than 59% of US stocks
Higher than 52% of US stocks
Higher than 73% of US stocks
Higher than 23% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XGN appears on the weeks it earns a place.
Exagen Inc. announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, with a Fireside Chat that will be webcast on the company's investor relations website.
Why it matters — The conference participation gives Exagen a platform to present its autoimmune testing business to investors and analysts.
The 7 Wall Street analysts covering Exagen, Inc. have a median 12-month price target of $8, with estimates ranging from $8 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Exagen, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Exagen, Inc. 44 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Exagen, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +70.9% from the last close, and Ticker Nerd's factor model ranks Exagen, Inc. 44 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Exagen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $10 over the next 12 months.
Exagen, Inc. returned -45.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Exagen Inc. is a commercial-stage diagnostics company specializing in autoimmune testing solutions under the AVISE brand in the United States.
The most recent item we track (GlobeNewsWire, 28 July 2026): "Exagen Inc. to Participate in Upcoming Investor Conference". Exagen Inc. announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, with a Fireside Chat that will be webcast on the company's investor relations website.
Exagen Inc. is a commercial-stage diagnostics company specializing in autoimmune testing solutions under the AVISE brand in the United States. It designs, develops, and commercializes testing products that enable healthcare providers to diagnose, prognose, and monitor complex rheumatic and autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other connective tissue diseases (CTDs). The lead product, AVISE CTD, supports differential diagnosis for patients with overlapping symptoms of various CTDs. Exagen Inc. also offers specialized biomarkers, including those for seronegative rheumatoid arthritis like anti-PAD4 markers and urinary panels for lupus nephritis, enhancing clinical utility in rheumatology. These tests play a key role in improving patient care by facilitating timely interventions and optimizing therapeutic strategies within the autoimmune diagnostics market. Headquartered in Carlsbad, California, Exagen Inc. focuses on advancing laboratory testing adoption among rheumatologists and supports research through presentations at medical conferences.
CEO Mr. John Aballi · 216 employees · United States · https://www.exagen.com